NovMetaHealth

For Your Healthy Life, NovMetaHealth

NovGP

Pipeline
NovGP
Program Target
Alzheimer's Disease
Patient Numbers
50 Million
Development Stage
Research
NovMetaHealth researches and develops NovGP, an Alzheimer’s disease medication of the first-in-class mechanism.

NovGP inhibits the aggregation of protein within cells by enhancing the function of AB protein cleaning through microglia in brain tissue.
Also, NovGP’s strong antioxidant function protects brain cells and has the treatment effect of degenerative brain disease.

Alzheimer’s disease treatment effect

NovGP Development Status

01

Clinical Development Status
1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022

Preclinical

Clinical phase 1

Clinical phase 2

02

Patent Application and Registration Status
Patents IP Protection
Degenerative brain disease patent 1 (KR)
Application
2019
Registration
2020
Patent expiration (expected) year
2039
Degenerative brain disease patent 2 (KR)
Application
2020
Patent expiration (expected) year
(2040)